You are here:
Direct Healthcare Professional Communication (DHPC) on terlipressin: Serious or fatal respiratory failure and sepsis/septic shock in patients with type 1 hepatorenal syndrome (type 1 HRS)
2022.12.01
Active substance: terlipressin
The marketing authorisation holder of terlipressin-containing medicines in agreement with the European Medicines Agency (EMA) and Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you that terlipressin may cause serious or fatal respiratory failure in patients with type 1 hepatorenal syndrome (type 1 HRS) at a frequency higher than previously known as well as to increase the risk of sepsis/septic shock in patients with type 1 HRS.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN